• 1

    JemalASiegelRWardE. Cancer statistics, 2009. CA Cancer J Clin2009;59:225249.

  • 2

    D’AmatoGSteinertDMMcAuliffeJCTrentJC. Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control2005;12:4456.

    • Search Google Scholar
    • Export Citation
  • 3

    FletcherCDBermanJJCorlessC. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol2002;33:459465.

  • 4

    ZahmSFraumeniJJ. The epidemiology of soft tissue sarcoma. Semin Oncol1997;24:504514.

  • 5

    CoindreJTerrierPGuillouL. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer2001;91:19141926.

    • Search Google Scholar
    • Export Citation
  • 6

    CormierJNPollockRE. Soft tissue sarcomas. CA Cancer J Clin2004;54:94109.

  • 7

    DomanskiHA. Fine-needle aspiration cytology of soft tissue lesions: diagnostic challenges. Diagn Cytopathol2007;35:768773.

  • 8

    AntonescuCR. The role of genetic testing in soft tissue sarcoma. Histopathology2006;48:13–21.

  • 9

    PfeiferJDHillDAO’SullivanMJDehnerLP. Diagnostic gold standard for soft tissue tumours: morphology or molecular genetics?Histopathology2000;37:485500.

    • Search Google Scholar
    • Export Citation
  • 10

    HillDAO’SullivanMJZhuX. Practical application of molecular genetic testing as an aid to the surgical pathologic diagnosis of sarcomas: a prospective study. Am J Surg Pathol2002;26:965977.

    • Search Google Scholar
    • Export Citation
  • 11

    SorensenPHLynchJCQualmanSJ. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar thabdomyosarcoma: a report from the Children’s Oncology Group. J Clin Oncol2002;20:26722679.

    • Search Google Scholar
    • Export Citation
  • 12

    GuillouLBenhattarJBonichonF. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol2004;22:40404050.

    • Search Google Scholar
    • Export Citation
  • 13

    LadanyiMAntonescuCRLeungDH. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res2002;62:135140.

    • Search Google Scholar
    • Export Citation
  • 14

    AntonescuCRTschernyavskySJDecusearaR. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res2001;7:39773987.

    • Search Google Scholar
    • Export Citation
  • 15

    GuillouLCoindreJBonichonF. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol1997;15:350362.

    • Search Google Scholar
    • Export Citation
  • 16

    DileoPDemetriGD. Update on new diagnostic and therapeutic approaches for sarcomas. Clin Adv Hematol Oncol2005;3:781791.

  • 17

    MocellinSRossiCBrandesANittiD. Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches. Cancer Treat Rev2006;32:927.

    • Search Google Scholar
    • Export Citation
  • 18

    BrennanMFCasperESHarrisonLB. The role of multimodality therapy in soft-tissue sarcoma. Ann Surg1991;214:328336.

  • 19

    KimBChenYLKirschDG. An effective preoperative three-dimensional radiotherapy target volume for extremity soft tissue sarcoma and the effect of margin width on local control. Int J Radiat Oncol Biol Phys2010; in press.

    • Search Google Scholar
    • Export Citation
  • 20

    FlemingJBBermanRSChengSC. Long-term outcome of patients with American Joint Committee on Cancer stage IIB extremity soft tissue sarcomas. J Clin Oncol1999;17:27722780.

    • Search Google Scholar
    • Export Citation
  • 21

    GerrandCHWunderJSKandelRA. Classification of positive margins after resection of soft-tissue sarcoma of the limb predicts the risk of local recurrence. J Bone Joint Surg Br2001;83:11491155.

    • Search Google Scholar
    • Export Citation
  • 22

    PistersPWLeungDHWoodruffJ. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol1996;14:16791689.

    • Search Google Scholar
    • Export Citation
  • 23

    LewisJJLeungDEspatJ. Effect of reresection in extremity soft tissue sarcoma. Ann Surg2000;231:655663.

  • 24

    ZagarsGKBalloMTPistersPW. Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy. Cancer2003;97:25442553.

    • Search Google Scholar
    • Export Citation
  • 25

    GhertMAAbuduADriverN. The indications for and the prognostic significance of amputation as the primary surgical procedure for localized soft tissue sarcoma of the extremity. Ann Surg Oncol2005;12:1017.

    • Search Google Scholar
    • Export Citation
  • 26

    StojadinovicAJaquesDPLeungDH. Amputation for recurrent soft tissue sarcoma of the extremity: indications and outcome. Ann Surg Oncol2001;8:509518.

    • Search Google Scholar
    • Export Citation
  • 27

    WilliardWCHajduSICasperESBrennanMF. Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg1992;215:269275.

    • Search Google Scholar
    • Export Citation
  • 28

    DeLaneyTFTrofimovAVEngelsmanMSuitHD. Advanced-technology radiation therapy in the management of bone and soft tissue sarcomas. Cancer Control2005;12:2735.

    • Search Google Scholar
    • Export Citation
  • 29

    LeibelSAFuksZZelefskyMJ. Intensity-modulated radiotherapy. Cancer J2002;8:164176.

  • 30

    DavisAO’SullivanBBellR. Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol2002;20:44724477.

    • Search Google Scholar
    • Export Citation
  • 31

    SadoskiCSuitHRosenbergA. Preoperative radiation, surgical margins, and local control of extremity sarcomas of soft tissues. J Surg Oncol1993;52:223230.

    • Search Google Scholar
    • Export Citation
  • 32

    AlektiarKMVelascoJZelefskyMJ. Adjuvant radiotherapy for margin-positive high-grade soft tissue sarcoma of the extremity. Int J Radiat Oncol Biol Phys2000;48:10511058.

    • Search Google Scholar
    • Export Citation
  • 33

    CahlonOSpiererMBrennanMF. Long-term outcomes in extremity soft tissue sarcoma after a pathologically negative re-resection and without radiotherapy. Cancer2008;112:27742779.

    • Search Google Scholar
    • Export Citation
  • 34

    AlektiarKMLeungDZelefskyMJ. Adjuvant brachytherapy for primary high-grade soft tissue sarcoma of the extremity. Ann Surg Oncol2002;9:4856.

    • Search Google Scholar
    • Export Citation
  • 35

    TranQNKimACGottschalkAR. Clinical outcomes of intraoperative radiation therapy for extremity sarcomas. Sarcoma2006;2006:91671.

  • 36

    ClarkMAThomasJM. Amputation for soft-tissue sarcoma. Lancet Oncol2003;4:335342.

  • 37

    RosenbergSATepperJGlatsteinE. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg1982;196:305315.

    • Search Google Scholar
    • Export Citation
  • 38

    BaldiniEHGoldbergJJennerC. Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. J Clin Oncol1999;17:32523259.

    • Search Google Scholar
    • Export Citation
  • 39

    LinPPGuzelVBPistersPW. Surgical management of soft tissue sarcomas of the hand and foot. Cancer2002;95:852861.

  • 40

    O’SullivanBDavisATurcotteR. Five-year results of a randomized phase III trial of pre-operative vs post-operative radiotherapy in extremity soft tissue sarcoma [abstract]. J Clin Oncol2004;22(Suppl 1):Abstract 9007.

    • Search Google Scholar
    • Export Citation
  • 41

    YangJCChangAEBakerAR. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol1998;16:197203.

    • Search Google Scholar
    • Export Citation
  • 42

    WilsonANDavisABellRS. Local control of soft tissue sarcoma of the extremity: the experience of a multidisciplinary sarcoma group with definitive surgery and radiotherapy. Eur J Cancer1994;30A:746751.

    • Search Google Scholar
    • Export Citation
  • 43

    PistersPWHarrisonLBLeungDH. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol1996;14:859868.

    • Search Google Scholar
    • Export Citation
  • 44

    AlektiarKMBrennanMFHealeyJHSingerS. Impact of intensity-modulated radiation therapy on local control in primary soft-tissue sarcoma of the extremity. J Clin Oncol2008;26:34403444.

    • Search Google Scholar
    • Export Citation
  • 45

    KepkaLDeLaneyTFSuitHDGoldbergSI. Results of radiation therapy for unresected soft-tissue sarcomas. Int J Radiat Oncol Biol Phys2005;63:852859.

    • Search Google Scholar
    • Export Citation
  • 46

    ClasbyRTillingKSmithMAFletcherCD. Variable management of soft tissue sarcoma: regional audit with implications for specialist care. Br J Surg1997;84:16921696.

    • Search Google Scholar
    • Export Citation
  • 47

    DemasBEHeelanRTLaneJ. Soft-tissue sarcomas of the extremities: comparison of MR and CT in determining the extent of disease. AJR Am J Roentgenol1988;150:615620.

    • Search Google Scholar
    • Export Citation
  • 48

    HannaSLFletcherBD. MR imaging of malignant soft-tissue tumors. Magn Reson Imaging Clin N Am1995;3:629650.

  • 49

    HeslinMJSmithJK. Imaging of soft tissue sarcomas. Surg Oncol Clin N Am1999;8:91107.

  • 50

    SchwabJHBolandPGuoT. Skeletal metastases in myxoid liposarcoma: an unusual pattern of distant spread. Ann Surg Oncol2007;14:15071514.

    • Search Google Scholar
    • Export Citation
  • 51

    SchwabJHBolandPJAntonescuC. Spinal metastases from myxoid liposarcoma warrant screening with magnetic resonance imaging. Cancer2007;110:18151822.

    • Search Google Scholar
    • Export Citation
  • 52

    TateishiUHasegawaTBeppuY. Prognostic significance of MRI findings in patients with myxoid-round cell liposarcoma. AJR Am J Roentgenol2004;182:725731.

    • Search Google Scholar
    • Export Citation
  • 53

    PorteraCAJrHoVPatelSR. Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer2001;91:585591.

    • Search Google Scholar
    • Export Citation
  • 54

    SchuetzeSM. Utility of positron emission tomography in sarcomas. Curr Opin Oncol2006;18:369373.

  • 55

    FolpeALLylesRHSprouseJT. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res2000;6:12791287.

    • Search Google Scholar
    • Export Citation
  • 56

    SchuetzeSMRubinBPVernonC. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer2005;103:339348.

    • Search Google Scholar
    • Export Citation
  • 57

    EaryJFO’SullivanFPowitanY. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging2002;29:11491154.

    • Search Google Scholar
    • Export Citation
  • 58

    GeerRJWoodruffJCasperESBrennanMF. Management of small soft-tissue sarcoma of the extremity in adults. Arch Surg1992;127:12851289.

  • 59

    KarakousisCPEmrichLJRaoUKhalilM. Limb salvage in soft tissue sarcomas with selective combination of modalities. Eur J Surg Oncol1991;17:7180.

    • Search Google Scholar
    • Export Citation
  • 60

    PistersPWO’SullivanBMakiRG. Evidence-based recommendations for local therapy for soft tissue sarcomas. J Clin Oncol2007;25:10031008.

    • Search Google Scholar
    • Export Citation
  • 61

    PistersPWPollockRELewisVO. Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas. Ann Surg2007;246:675681; discussion 681–682.

    • Search Google Scholar
    • Export Citation
  • 62

    KraybillWGHarrisJSpiroIJ. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group trial 9514. J Clin Oncol2006;24:619625.

    • Search Google Scholar
    • Export Citation
  • 63

    GrobmyerSRMakiRGDemetriGD. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol2004;15:16671672.

    • Search Google Scholar
    • Export Citation
  • 64

    DeLaneyTF SISuitHDGebhardtMC. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys2003;56:11171127.

    • Search Google Scholar
    • Export Citation
  • 65

    PistersPWPatelSRVarmaDG. Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution. J Clin Oncol1997;15:34813487.

    • Search Google Scholar
    • Export Citation
  • 66

    PistersPWBalloMTPatelSR. Preoperative chemoradiation treatment strategies for localized sarcoma. Ann Surg Oncol2002;9:535542.

  • 67

    MakiRG. Role of chemotherapy in patients with soft tissue sarcomas. Expert Rev Anticancer Ther2004;4:229236.

  • 68

    TierneyJFMosseriVStewartLA. Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised clinical trials. Br J Cancer1995;72:469475.

    • Search Google Scholar
    • Export Citation
  • 69

    Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet1997;350:16471654.

    • Search Google Scholar
    • Export Citation
  • 70

    BramwellVRouesseJStewardW. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma—reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol1994;12:11371149.

    • Search Google Scholar
    • Export Citation
  • 71

    CormierJNHuangXXingY. Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J Clin Oncol2004;22:45674574.

    • Search Google Scholar
    • Export Citation
  • 72

    FrustaciSDe PaoliABidoliE. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology2003;65:8084.

  • 73

    FrustaciSGherlinzoniFDe PaoliA. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol2001;19:12381247.

    • Search Google Scholar
    • Export Citation
  • 74

    WollPJvan GlabbekeMHohenbergerP. Adjuvant chemotherapy (CT) with doxorubicin and ifosfamide in resected soft tissue sarcoma (STS): interim analysis of a randomised phase III trial [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 10008.

    • Search Google Scholar
    • Export Citation
  • 75

    AlektiarKMLeungDZelefskyMJBrennanMF. Adjuvant radiation for stage II-B soft tissue sarcoma of the extremity. J Clin Oncol2002;20:16431650.

    • Search Google Scholar
    • Export Citation
  • 76

    AntmanKCrowleyJBalcerzakS. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol1993;11:12761285.

    • Search Google Scholar
    • Export Citation
  • 77

    AntmanKHJudsonEA. Dana-Farber Cancer Institute studies in advanced sarcoma. Semin Oncol1990;1:715.

  • 78

    BramwellVHAndersonDCharetteML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev2003;CD003293.

    • Search Google Scholar
    • Export Citation
  • 79

    EdmonsonJRyanLBlumR. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol1993;11:12691275.

    • Search Google Scholar
    • Export Citation
  • 80

    EliasARyanLSulkesA. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol1989;7:12081216.

    • Search Google Scholar
    • Export Citation
  • 81

    LoriganPVerweijJPapaiZ. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol2007;25:31443150.

    • Search Google Scholar
    • Export Citation
  • 82

    SantoroATurszTMouridsenH. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol1995;13:15371545.

    • Search Google Scholar
    • Export Citation
  • 83

    ZalupskiMMetchBBalcerzakS. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst1991;83:926932.

    • Search Google Scholar
    • Export Citation
  • 84

    SiehlJMThielESchmittelA. Liposomal anthracyclines and ifosfamide in the first line treatment of advanced soft tissue sarcomas: a two cohort phase II study [abstract]. J Clin Oncol2006;24(Suppl 1):Abstract 9563.

    • Search Google Scholar
    • Export Citation
  • 85

    SiehlJMThielESchmittelA. Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: results of a phase II study. Cancer2005;104:611617.

    • Search Google Scholar
    • Export Citation
  • 86

    HensleyMLMakiRVenkatramanE. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol2002;20:28242831.

    • Search Google Scholar
    • Export Citation
  • 87

    MakiRGWathenJKPatelSR. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol2007;25:27552763.

    • Search Google Scholar
    • Export Citation
  • 88

    LeuKMOstruszkaLJShewachD. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treament with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol2004;22:17061712.

    • Search Google Scholar
    • Export Citation
  • 89

    BayJORay-CoquardIFayetteJ. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer2006;119:706711.

    • Search Google Scholar
    • Export Citation
  • 90

    DileoPMorganJAZahriehD. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Cancer2007;109:18631869.

    • Search Google Scholar
    • Export Citation
  • 91

    Garcia del MuroXLopez-PousaAMartinJ. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. Cancer2005;104:17061712.

    • Search Google Scholar
    • Export Citation
  • 92

    TalbotSMKeohanMLHesdorfferM. A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma. Cancer2003;98:19421946.

    • Search Google Scholar
    • Export Citation
  • 93

    Le CesneABlayJYJudsonI. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group trial. J Clin Oncol2005;23:576584.

    • Search Google Scholar
    • Export Citation
  • 94

    Garcia-CarboneroRSupkoJGManolaJ. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol2004;22:14801490.

    • Search Google Scholar
    • Export Citation
  • 95

    Garcia-CarboneroRSupkoJGMakiRG. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol2005;23:54845492.

    • Search Google Scholar
    • Export Citation
  • 96

    YovineARiofrioMBlayJY. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol2004;22:890899.

    • Search Google Scholar
    • Export Citation
  • 97

    LaverdiereCKolbEASupkoJG. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer2003;98:832840.

    • Search Google Scholar
    • Export Citation
  • 98

    IsselsRDLindnerLHWustP. Regional hyperthermia (RHT) improves response and survival when combined with systemic chemotherapy in the management of locally advanced, high grade soft tissue sarcomas (STS) of the extremities, the body wall and the abdomen: a phase III randomised pros [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 10009.

    • Search Google Scholar
    • Export Citation
  • 99

    IsselsRSchlemmerM. Current trials and new aspects in soft tissue sarcoma of adults. Cancer Chemother Pharmacol2002;49(Suppl 1):S48.

  • 100

    GrunhagenDJBrunsteinFten HagenTL. TNF-based isolated limb perfusion: a decade of experience with antivascular therapy in the management of locally advanced extremity soft tissue sarcomas. Cancer Treat Res2004;120:6579.

    • Search Google Scholar
    • Export Citation
  • 101

    GrunhagenDJde WiltJHGravelandWJ. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer2006;106:17761784.

    • Search Google Scholar
    • Export Citation
  • 102

    WhooleyBPMooneyMMGibbsJFKraybillWG. Effective follow-up strategies in soft tissue sarcoma. Semin Surg Oncol1999;17:8387.

  • 103

    WhooleyBPGibbsJFMooneyMM. Primary extremity sarcoma: what is the appropriate follow-up?Ann Surg Oncol2000;7:914.

  • 104

    KaneJMIII. Surveillance strategies for patients following surgical resection of soft tissue sarcomas. Curr Opin Oncol2004;16:328332.

    • Search Google Scholar
    • Export Citation
  • 105

    LewisJJLeungDCasperES. Multifactorial analysis of long-term follow-up (more than 5 years) of primary extremity sarcoma. Arch Surg1999;134:190194.

    • Search Google Scholar
    • Export Citation
  • 106

    FlemingJBCantorSBVarmaDG. Utility of chest computed tomography for staging in patients with T1 extremity soft tissue sarcomas. Cancer2001;92:863868.

    • Search Google Scholar
    • Export Citation
  • 107

    SingerSAntmanKCorsonJMEberleinTJ. Long-term salvageability for patients with locally recurrent soft-tissue sarcomas. Arch Surg1992;127:548553; discussion 553–544. References 108–127 are cited in the section on “Retroperitoneal/Intra-Abdominal Soft Tissue Sarcomas” and are available in the version of these guidelines online at www.NCCN. org.

    • Search Google Scholar
    • Export Citation
  • 128

    HirotaSIsozakiKMoriyamaY. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science1998;279:577580.

  • 129

    HeinrichMCCorlessCLDuensingA. PDGFRA activating mutations in gastrointestinal stromal tumors. Science2003;299:708710.

  • 130

    HirotaSOhashiANishidaT. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology2003;125:660667.

    • Search Google Scholar
    • Export Citation
  • 131

    MiettinenMLasotaJ. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol2006;23:7083.

  • 132

    MiettinenMLasotaJ. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med2006;130:14661478.

    • Search Google Scholar
    • Export Citation
  • 133

    DemetriGDvon MehrenMBlankeCD. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med2002;347:472480.

    • Search Google Scholar
    • Export Citation
  • 134

    BlankeCDDemetriGDvon MehrenM. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol2008;26:620625.

    • Search Google Scholar
    • Export Citation
  • 135

    VerweijJCasaliPGZalcbergJ. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet2004;364:11271134.

    • Search Google Scholar
    • Export Citation
  • 136

    BlankeCDRankinCDemetriGD. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol2008;26:626632.

    • Search Google Scholar
    • Export Citation
  • 137

    DagherRCohenMWilliamsG. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res2002;8:30343038.

    • Search Google Scholar
    • Export Citation
  • 138

    LasotaJMiettinenM. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology2008;53:245266.

    • Search Google Scholar
    • Export Citation
  • 139

    HeinrichMCCorlessCLDemetriGD. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol2003;21:43424349.

    • Search Google Scholar
    • Export Citation
  • 140

    Debiec-RychterMDumezHJudsonI. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer2004;40:689695.

    • Search Google Scholar
    • Export Citation
  • 141

    HeinrichMCOwzarKCorlessCL. Correlation of kinase genotype and clinical outcome in the North American Intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol2008;26:53605367.

    • Search Google Scholar
    • Export Citation
  • 142

    ZalcbergJRVerweijJCasaliPG. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer2005;41:17511757.

    • Search Google Scholar
    • Export Citation
  • 143

    Debiec-RychterMSciotRLe CesneA. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer2006;42:10931103.

    • Search Google Scholar
    • Export Citation
  • 144

    Gastrointestinal stromal tumor meta-analysis group comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 Patients. J Clin Oncol2010;28:12471253.

    • Search Google Scholar
    • Export Citation
  • 145

    EisenbergBLHarrisJBlankeCD. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol2009;99:4247.

    • Search Google Scholar
    • Export Citation
  • 146

    McAuliffeJCHuntKKLazarAJ. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol2009;16:910919.

    • Search Google Scholar
    • Export Citation
  • 147

    EisenbergBLJudsonI. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol2004;11:465475.

    • Search Google Scholar
    • Export Citation
  • 148

    GoldJSDematteoRP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg2006;244:176184.

  • 149

    DeMatteoRPLewisJJLeungD. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg2000;231:5158.

    • Search Google Scholar
    • Export Citation
  • 150

    DematteoRPAntonescuCRChadaramV. Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: safety results from the U.S. Intergroup phase II trial ACOSOG Z9000 [abstract]. J Clin Oncol2005;23(Suppl 1):Abstract 9009.

    • Search Google Scholar
    • Export Citation
  • 151

    DematteoRPBallmanKVAntonescuCR. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet2009;373:10971104.

    • Search Google Scholar
    • Export Citation
  • 152

    GuilhotF. Indications for imatinib mesylate therapy and clinical management. Oncologist2004;9:271281.

  • 153

    TrentJCPatelSSZhangJ. Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. Cancer2010;116:184192.

    • Search Google Scholar
    • Export Citation
  • 154

    BenjaminRSDebiec-RychterMLe CesneA. Gastrointestinal stromal tumors II: medical oncology and tumor response assessment. Semin Oncol2009;36:302311.

    • Search Google Scholar
    • Export Citation
  • 155

    MaledduAPantaleoMANanniniM. Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (review). Oncol Rep2009;21:13591366.

    • Search Google Scholar
    • Export Citation
  • 156

    HeinrichMCMcArthurGADemetriGD. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol2006;24:11951203.

    • Search Google Scholar
    • Export Citation
  • 157

    DemetriGDvan OosteromATGarrettCR. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet2006;368:13291338.

    • Search Google Scholar
    • Export Citation
  • 158

    GeorgeSBlayJYCasaliPG. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer2009;45:19591968.

    • Search Google Scholar
    • Export Citation
  • 159

    ChuDLacoutureMEWeinerEWuS. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer2009;7:1119.

    • Search Google Scholar
    • Export Citation
  • 160

    ZhuXStergiopoulosKWuS. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol2009;48:917.

    • Search Google Scholar
    • Export Citation
  • 161

    ChuTFRupnickMAKerkelaR. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet2007;370:20112019.

  • 162

    TorinoFCorselloSMLongoR. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol2009;6:219228.

    • Search Google Scholar
    • Export Citation
  • 163

    SepePSMopartyBPitmanMB. EUS-guided FNA for the diagnosis of GI stromal cell tumors: sensitivity and cytologic yield. Gastrointest Endosc2009;70:254261.

    • Search Google Scholar
    • Export Citation
  • 164

    Van den AbbeeleAD. The lessons of GIST—PET and PET/CT: a new paradigm for imaging. Oncologist2008;13(Suppl 2):813.

  • 165

    Van Den AbbeeleADBadawiRDManolaJ. Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning [abstract]. J Clin Oncol2004;22(Suppl 1):Abstract 3012.

    • Search Google Scholar
    • Export Citation
  • 166

    BlayJYLe CesneARay-CoquardI. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol2007;25:11071113.

    • Search Google Scholar
    • Export Citation
  • 167

    DematteoRPGoldJSSaranL. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer2008;112:608615.

    • Search Google Scholar
    • Export Citation
  • 168

    GoldJSGonenMGutierrezA. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol2009;10:10451052.

    • Search Google Scholar
    • Export Citation
  • 169

    RautCPPosnerMDesaiJ. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol2006;24:23252331.

    • Search Google Scholar
    • Export Citation
  • 170

    WiebeLKaszaKEMakiRG. Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): a phase II trial of the University of Chicago Phase II Consortium [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 10502.

    • Search Google Scholar
    • Export Citation
  • 171

    BlayJYCasaliPGReichardtP. A phase I study of nilotinib alone and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (GIST): study update [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 10553.

    • Search Google Scholar
    • Export Citation
  • 172

    DemetriGDLo RussoPMacPhersonIR. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res2009;15:62326240.

    • Search Google Scholar
    • Export Citation
  • 173

    FumagalliECocoPMorosiC. Rechallenge with imatinib in GIST patients resistant to second or third line therapy. Presented at the 2009 Connective Tissue Oncology Society 15th Annual Meeting; November 5–7, 2009; Miami Beach, Florida. Abstract 39404. References 174–201 are cited in the section on “Desmoid Tumors (Fibromatoses)” and are available in the version of these guidelines online at www.NCCN.org.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 485 485 47
PDF Downloads 58 58 8
EPUB Downloads 0 0 0